問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5239Cases

2024-08-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-12-01 - 2023-12-31

Phase III

A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements-FOENIX-CCA3

  • Condition/Disease

    Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

  • Test Drug

    Futibatinib（TAS-120）

Participate Sites
6Sites

Recruiting6Sites

2019-04-01 - 2022-06-20

Phase III

A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    Lebrikizumab

Participate Sites
7Sites

Recruiting7Sites

2019-10-01 - 2021-06-30

Phase II

A Phase IIa, Double-Blind, Single Dose, Randomized, Placebo-ControlledStudy to Evaluate the Safety, Tolerability, and Potential Efficacy of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)

  • Condition/Disease

    Acute Ischemic Stroke

  • Test Drug

    LT3001 drug product

Participate Sites
6Sites

Recruiting4Sites

Study ended2Sites

趙雅琴
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2020-10-01 - 2023-06-05

Phase II

A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    ABI-H2158

Participate Sites
5Sites

Not yet recruiting5Sites

2020-08-14 - 2027-07-24

Phase III

A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  • Condition/Disease

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    DEBIO 1143

Participate Sites
10Sites

Recruiting8Sites

Terminated2Sites

2018-07-30 - 2022-08-13

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

王鵬惠
Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2018-06-04 - 2020-01-19

Phase III

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1)

  • Condition/Disease

    Age-Related Macular Degeneration (AMD)

  • Test Drug

    Conbercept

Participate Sites
5Sites

Recruiting5Sites

2018-04-20 - 2019-03-26

Phase II

A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    varlitinib

Participate Sites
3Sites

Terminated3Sites

2019-09-01 - 2022-12-31

Phase II

A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)

  • Condition/Disease

    Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies

  • Test Drug

    ME-401

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

1 456 457 458 459 460 524
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB